Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
QuintilesIMS
Cipla
Baxter
McKinsey
Dow
US Army
AstraZeneca

Generated: November 19, 2018

DrugPatentWatch Database Preview

ZOLINZA Drug Profile

« Back to Dashboard

When do Zolinza patents expire, and what generic alternatives are available?

Zolinza is a drug marketed by Merck and is included in one NDA. There are nine patents protecting this drug.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.

Drug patent expirations by year for ZOLINZA
Generic Entry Opportunity Date for ZOLINZA
Generic Entry Date for ZOLINZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZOLINZA
Synonyms for ZOLINZA
149647-78-9
1t69
1zz1
4lxz
58IFB293JI
647S789
8-(hydroxyamino)-8-oxo-N-phenyl-octanamide
AB0009911
AB00375377-07
AB00375377-08
AB00375377-09
AB01644613_25
AC-1923
AC1L1K2K
AKOS015966648
AM20030018
AN-5256
ANW-43951
AOB6083
BC677687
BCPP000018
BDBM19149
BP-30216
BRD-K81418486-001-01-2
BRD-K81418486-001-10-3
BRD-K81418486-001-12-9
BRD-K81418486-001-17-8
CAS-149647-78-9
cc-95
CCG-208659
CCRIS 8456
CHEBI:45716
CHEMBL98
cid_5311
CS-0589
CTK8B4125
D06320
D0E7PQ
DB02546
DG-0025
DSSTox_CID_21133
DSSTox_GSID_41133
DSSTox_RID_79632
DTXSID6041133
FT-0082592
FT-0650593
GTPL6852
HMS2219L20
HMS3264D20
HMS3327C12
HMS3650D09
HMS3654G11
HY-10221
K-4759
KB-60639
KS-00000H3B
LP008054
LS-186548
LS-186997
LS-187780
MCULE-4234367506
Merck brand of Vorinostat
MFCD00945317
MK-0683
MK0683
MLS001065855
MLS006011941
MolPort-003-850-293
N-Hydroxy-N'-phenyl octanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
n-hydroxy-n'-phenyl-octanediamide
N-hydroxy-N'-phenyloctanediamide
N-hydroxy-N''-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N'-hydroxy-N-phenyloctanediamide
N1-hydroxy-N8-phenyl-octanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-01
NCGC00168085-02
NCGC00168085-03
NCGC00168085-04
NCGC00168085-05
NHNPODA
NSC-701852
NSC-748799
NSC-759852
NSC701852
NSC748799
NSC759852
Octanediamide, N-hydroxy-N'-phenyl-
Octanediamide, N1-hydroxy-N8-phenyl
Octanediamide, N1-hydroxy-N8-phenyl-
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
P111011
Pharmakon1600-01502267
QCR-121
RP29421
RT-015807
s1047
SAHA
SAHA cpd
SAHA, >=98% (HPLC)
SAHA, Suberoylanilide hydroxamic acid
SC-20040
SCHEMBL9018
SHH
SK1390
SKI390
SMR000486344
SR-05000000373
SR-05000000373-6
SR-05000000373-8
Suberanilohydroxamic acid
suberoylanilide hydroxamic acid
Suberoylanilide hydroxamic acid (SAHA)
Suberoylanilidehydroxamic Acid
SW-064652
SYN3006
Tox21_112605
Tox21_112605_1
Tox21_113623
UNII-58IFB293JI
Vorinostat
Vorinostat - SAHA
Vorinostat (HDAC inhibitor)
Vorinostat (JAN/USAN)
Vorinostat (SAHA, MK0683)
Vorinostat (SAHA)
Vorinostat [USAN]
Vorinostat MSD
Vorinostat, SAHA, suberoylanilide hydroxamic acid
Vorinostat,CAS:149647-78-9
Vorinostat,SAHA,Zolinza,MK-0683
vorinostatum
W-201327
WAEXFXRVDQXREF-UHFFFAOYSA-N
WIN64652
Z1541632802
ZINC1543873
Zolinza (TN)
Zolinza (TN) (Merck)
Zolinza, MK-0683, SAHA
Zolinza; SAHA

US Patents and Regulatory Information for ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for ZOLINZA

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
QuintilesIMS
Cipla
Baxter
McKinsey
Dow
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.